摘要
Combination antiretroviral therapy(ART)reduced AIDS-related mortality and increased survival among patients living with HIV by interrupting HIV replication,enhancing immune recovery,and preventing the onset of opportunistic infections[1].In China,ART has rapidly been scaled up since the beginning of the National Free Antiretroviral Treatment Program(NFATP)in 2003[2].By the end of 2016,489,411 individuals diagnosed with HIV were receiving free antiretroviral treatment in China.China is firmly committed to reducing overall AIDS-related mortality and HIV incidence within the country.However,similar to other low-and middle-income countries,the NFATP is challenged by high mortality and attrition shortly after patients initiate ART[3].
基金
the Guangxi Medical and Health Project[Z20170126]
the National Natural Science Foundation of China[Grant numbers 11971479,81502862,81460510,81360442,and 91546203]
Guangxi Science and Technology Bureau[Grant number AB16380213]
Guangxi Bagui Honor Scholarship,Ministry of Science and Technology of China[2018ZX10721102-006 and 2017ZX10201101]
Guangxi Key Laboratory of AIDS Prevention Control and Translation,and Chinese State Key Laboratory of Infectious Disease Prevention and Control.
